EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access

NFE2L2 and ferroptosis resistance in cancer therapy

Daolin Tang, Rui Kang

Cancer Drug Resistance · 25.10.2024

DOI: 10.20517/cdr.2024.123 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cancer Drug Resistance, online erschienen am 25.10.2024. Verfasst von Daolin Tang und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, University of Texas Southwestern Medical Center, Dallas, TA 75390, USA. Die Arbeit wurde bisher 30-mal zitiert (Crossref) und nennt 143 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

NFE2-like basic leucine zipper transcription factor 2 (NFE2L2, also known as NRF2), is a key transcription factor in the cellular defense against oxidative stress, playing a crucial role in cancer cell survival and resistance to therapies. This review outlines the current knowledge on the link between NFE2L2 and ferroptosis - a form of regulated cell death characterized by iron-dependent lipid peroxidation - within cancer cells. While NFE2L2 activation can protect normal cells from oxidative damage, its overexpression in cancer cells contributes to drug resistance by upregulating antioxidant defenses and inhibiting ferroptosis. We delve into the molecular pathways of ferroptosis, highlighting the involvement of NFE2L2 and its target genes, such as NQO1 , HMOX1 , FTH1 , FTL , HERC2 , SLC40A1 , ABCB6 , FECH , PIR , MT1G , SLC7A11 , GCL , GSS , GSR , GPX4 , AIFM2 , MGST1 , ALDH1A1 , ALDH3A1 , and G6PD , in ferroptosis resistance. Understanding the delicate balance between NFE2L2’s protective and deleterious roles could pave the way for novel therapeutic strategies targeting NFE2L2 to enhance the efficacy of ferroptosis inducers in cancer therapy.

Schlagwörter

Stichwörter der Autor:innen

Cancer therapyNFE2L2drug resistanceferroptosisoxidative stress

Autor:innen und Institutionen

  • Department of Surgery, University of Texas Southwestern Medical Center, Dallas, TA 75390, USA.

Förderung

  • NCI NIH HHS

Zitieren

APA

Tang, D., & Kang, R. (2024). NFE2L2 and ferroptosis resistance in cancer therapy. Cancer Drug Resistance. https://doi.org/10.20517/cdr.2024.123

Vancouver

Tang D, Kang R. NFE2L2 and ferroptosis resistance in cancer therapy. Cancer Drug Resistance. 2024. doi:10.20517/cdr.2024.123

BibTeX
@article{Tang2024,
  author = {Tang, Daolin and Kang, Rui},
  title = {NFE2L2 and ferroptosis resistance in cancer therapy},
  journal = {Cancer Drug Resistance},
  year = {2024},
  doi = {10.20517/cdr.2024.123}
}
Kostenlos starten →